CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The Targeted Anti-Cancer Therapies project trains early-stage researchers in the development of antibody-drug conjugates for cancer treatment. It focuses on innovative methods for creating more effective therapies that specifically target cancer cells while sparing healthy ones.
Antibody-Drug Conjugates (ADCs) are fast growing classes of oncology therapeutics.
They consist in a highly potentcytotoxic drug connected via a linker to an antibody that is specifically targeting certain tumor markers.
By combining thecytotoxicity of the drug and the targeting properties of the antibody, ADCs kill cancer cells whilst leaving the healthy cellsunaffected, a marked improvement compared to classical chemotherapies.
However, limitations still exist which could fuelthe development o…
UNIVERSITE DE STRASBOURG
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, London
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
THE QUEEN'S UNIVERSITY OF BELFAST
United Kingdom, Belfast
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Netherlands, Wageningen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
